Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PSEUDO-12 is an oral extended-release suspension approved in 1987 by UCB Pharma as a small-molecule NDA. The mechanism of action and therapeutic indication are unknown, limiting clinical context assessment. The extended-release formulation suggests chronic dosing for a condition requiring sustained drug exposure.
Product nearing loss of exclusivity with moderate competitive pressure (30/100); brand team likely focused on lifecycle management and generic defense rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job openings signal minimal active hiring around PSEUDO-12, reflecting its mature/LOE stage. Career value is primarily in defensive commercial execution, regulatory compliance, and transition planning rather than growth or innovation.
Worked on PSEUDO-12 at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.